GTC
AUPH icon

Ghost Tree Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

Ghost Tree Capital’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-550,000
Closed -$8.1M – 48
2020
Q3 		$8.1M Hold
550,000
– – 2.34% 14
2020
Q2 		$8.94M Buy
550,000
+150,000
+38% +$2.4M 2.36% 19
2020
Q1 		$5.8M Sell
400,000
-200,000
-33% -$3.53M 1.54% 17
2019
Q4 		$12.2M Buy
+600,000
New +$5.53M 2.31% 14

Other funds holding AUPH

HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Ghost Tree Capital's AUPH Position: Q4 2020 in Review

Ghost Tree Capital sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2020, closing a stake of 550,000 shares — an estimated $8.1M sold.

Ghost Tree Capital first reported a position in AUPH in Q4 2019 and held it in 4 quarters. The position peaked at $12.2M in Q4 2019. 145 funds tracked by Wall St. Rank hold AUPH as of Q4 2020.

  • Ghost Tree Capital reported no remaining Aurinia Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Ghost Tree Capital sold 550,000 Aurinia Pharmaceuticals shares in Q4 2020, an estimated $8.1M.
  • Ghost Tree Capital first reported a position in Aurinia Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • Ghost Tree Capital's Aurinia Pharmaceuticals position peaked at $12.2M in Q4 2019.
  • 145 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2020.

Based on Ghost Tree Capital's 13F filing for Q4 2020, filed 16 Feb 2021.